Therapy with cultured T cells: Principles revisited

Immunological Reviews

Volumn 157, Issue , 1997, Pages 177-194

  Cheever, Martin A ^a   Chen, Wei ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2;

CANCER; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; CLINICAL TRIAL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOCYTE CLONE; LYMPHOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; CELLS, CULTURED; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 0030763687     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00982.x     Document Type: Review

References (56)

1. Walter EA, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038-1044.
2. Rosenberg SA, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;171:907-913.
3. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-106.
4. Papadopoulos EB, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
5. Fass L, Fefer A. Studies of adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res 1972;32:997-1001.
6. Cheever M, Greenberg P, Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 1980;125:711-714.
7. Cheever M, Greenberg P, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin-2. J Immunol 1981;126:1318-1322.
8. Chen W, Reese VA, Cheever MA. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2. J Immunol 1990;144:3659-3666.
9. Cheever M, Thompson D, Klarnet J, Greenberg P. Antigen-driven long-term cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy and persist long-term as functional memory T cells. J Exp Med 1986;163:1100-1112.
10. Klarnet JP, et al. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J Immunol 1987;138:4012-4017.
11. Greenberg PD, Cheever MA, Fefer A. Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia. Cancer Res 1980;40:4428-4432.
12. Greenberg PD, Cheever MA. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol 1984;133:3401-3407.
13. Chen W, Cheever MA. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression. J Immunol 1994;152:4767-4774.
14. Cheever MA, Greenberg PD, Fefer A, Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982;155:968-980.
15. Cheever MA, et al. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J Immunol 1984;132:2259-2265.
16. Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. J Immunol 1985;134:3895-3900.
17. Cheever MA, Kempf RA, Fefer A. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J Immunol 1977;119:714-718.
18. Cheever MA, Greenberg PD, Fefer A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. II. Comparison of cells cultured with and without tumor to noncultured immune cells. J Immunol 1978;121:2220-2227.
19. Greenberg PD, Cheever M, Fefer A. Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells. J Immunol 1979;123:515-522.
20. Peace DJ, Cheever MA. Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine leukemia. J Exp Med 1989;169:161-173.
21. Zhang L, Miller RG, Zhang J. Characterization of apoptosis-resistant antigen-specific T cells in vivo. J Exp Med 1996;183:2065-2073.
22. Zhang L. The fate of adoptively transferred antigen-specific T cells in vivo. Eur J Immunol 1996;26:2208-2214.
23. Cochrane C, Dixon F. Antibody production by transferred cells. Adv Immunol 1962;2:205-239.
24. Owens AH Jr, Samos GW. The induction of graft versus host disease in mice treated with cyclophosphamide. J Exp Med 1968;128:277-291.
25. Rondinone SN, Giovanniello OA, Barrios HA, Nota NR. Effect of fractional cyclophosphamide dosage on sheep red blood cell-delayed-type hypersensitivity response in mice. J Immunol 1983;130:1600-1603.
26. Rosenberg SA, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-1166.
27. Pockaj BA, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731-1737.
28. Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma, results in 36 patients. Eur J Cancer 1995;5:698-708.
29. Rosenberg SA, et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-578.
30. Culver K, et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA 1991;88:3155-3159.
31. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-586.
32. + suppressors of delayed sensitivity precedes the production of suppressors of protective immunity [published erratum appears in J Exp Med 1986;164:2131]. J Exp Med 1986;164:1179-1192.
33. + suppressor-inducer T-cells. Cancer Res 1988;48:1671-1675.
34. Quesenberry P, Cohen H, Levin J, Sullivan R, Bealmear P, Ryan M. Effects of bacterial infection and irradiation on serum colony-stimulating factor levels in tolerant and nontolerant CF1 mice. Blood 1978;51:229-244.
35. Zidar BL, Shadduck RK. Serum colony-stimulating and colony-inhibitory activity in response to neutropenia. J Lab Clin Med 1978;91:584-591.
36. Lotze MT, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135:2865-2875.
37. Jablons DM, et al. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol 1989;142:1542-1547.
38. Sussman JJ, Shu S, Sondak VK, Chang AE. Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1994;1:296-306.
39. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991;146:4414-4420.
40. Haqqi TM, Qu XM, Anthony D, Ma J, Sy MS. Immunization with T cell receptor V beta chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice. J Clin Invest 1996;97:2849-2858.
41. Mor F, Cohen IR. T cell vaccines for autoimmune diseases. Ann N Y Acad Sci 1993;685:784-787.
42. Riddell SR, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.
43. Melief CJ, Kast WM. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. Ciba Found Symp 1994;187:97-104.
44. Mandelboim O, et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995;1:1179-1183.
45. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
46. + helper T lymphocytes recognize distinct friend murine leukemia virus-encoded antigens. J Exp Med 1989;169:457-167.
47. Chen VJ, Qin H, Chesebro B, Cheever MA. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 1996;70:7773-7782.
48. Prats AC, De-Billy G, Wang P, Darlix JL. CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. J Mol Biol 1989;205:363-372.
49. Dickson C, Eisenman R, Fan H, Hunter E, Teich N. Protein biosynthesis and assembly In: Weiss, Teich, Varmus, Coffin, eds. RNA tumor viruses. Molecular biology of tumor viruses. Cold Spring Harbor Laboratory: Cold Spring Harb Symp Quant Biol; 1982.p.513-648.
50. Falk K, Rötschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-296.
51. + CTL elicited by in vitro or in vivo priming with tumor-associated peptides can effectively eradicate established leukmeia. FASEB 1996;10:1438.
52. Cheever MA, et al. Immunity to oncogenic proteins. Immunol Rev 1995;145:33-59.
53. Disis M, Cheever M. Oncogenic proteins as tumor antigens. In: Alt F, Marrack P, eds. Curr Opin Immunol 1996;8:637-642.
54. Disis ML, Cheever MA. HER-2/neu protein: a target for antigen specific immunotherapy of human cancer. Adv Cancer Res 1997 (In press).
55. Bex F, et al. Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primed lymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. Blood 1994;84:3317-3326.
56. Shouval D, Ilan Y. Adoptive transfer of immunity to hepatitis B: development of the concept and evolution of the research project for targeted immunotherapy against hepatic cells which express a viral antigen. Adv Drug Delivery Rev 1995:17:317-320.